Hospital
University Hospitals Geneva Medical Center
University Hospitals Geneva Medical Center was paid $9.85M by Medicaid between Jan 2018 and Dec 2024, across 184 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoUNIVERSITY HOSPITALS GENEVA MEDICAL CENTER
GENEVA, OH 44041
GENEVA, OH 44041
33aNPI1225128432assigned 10/16/2006
33bProvider typeCritical Access Hospital
28Total paid$9.85M
24GClaims288,494
24DCodes billed184
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#8 of 26
Median peer was paid$5.33M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SCHILLERO, ANTHONY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,684 | $730K | |
| 2019 | 20,206 | $565K | |
| 2020 | 15,173 | $539K | |
| 2021 | 25,965 | $764K | |
| 2022 | 29,662 | $977K | |
| 2023 | 102,481 | $3.32M | |
| 2024incomplete | 71,323 | $2.96M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 16,321 | 14,993 | $2.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 12,896 | 11,066 | $1.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 8,976 | 7,925 | $1.20M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 4,124 | 3,114 | $988K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.1% | 2,528 | 2,103 | $600K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 2,302 | 1,849 | $546K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.1% | 3,045 | 2,235 | $402K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.8% | 1,079 | 839 | $281K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.8% | 1,084 | 632 | $182K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 802 | 646 | $181K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 810 | 674 | $169K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 2,297 | 728 | $155K |
172 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.5% | 1,984 | $146K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 412 | $109K |
| 80053 | Comprehensive metabolic panel | <1% | 18,119 | $86K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 396 | $82K |
| G0378 | Hospital observation service, per hour | <1% | 1,863 | $73K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 755 | $71K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 507 | $68K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 467 | $67K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,216 | $48K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 64 | $48K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,209 | $44K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,920 | $43K |
| 71250 | <1% | 692 | $39K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 174 | $33K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 295 | $31K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 236 | $31K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 555 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,655 | $28K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,688 | $27K |
| 96367 | <1% | 627 | $26K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,727 | $22K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 117 | $22K |
| 84484 | <1% | 10,760 | $22K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 634 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,121 | $19K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 193 | $17K |
| 97161 | <1% | 273 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 788 | $14K |
| 82805 | <1% | 722 | $13K | |
| 83605 | <1% | 6,920 | $12K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,792 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,922 | $10K |
| 72131 | <1% | 129 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 113 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 555 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 835 | $9K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 18 | $8K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 22 | $8K |
| 85027 | <1% | 5,169 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,297 | $7K |
| 73630 | <1% | 485 | $7K | |
| 96376 | <1% | 1,205 | $6K | |
| 93971 | <1% | 99 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,690 | $6K |
| 76642 | <1% | 55 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,022 | $6K |
| 94664 | <1% | 599 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 129 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,183 | $5K |
| 73030 | <1% | 281 | $4K | |
| 80320 | <1% | 219 | $4K | |
| 74018 | <1% | 163 | $4K | |
| 73130 | <1% | 327 | $4K | |
| 82140 | <1% | 264 | $4K | |
| 73610 | <1% | 312 | $3K | |
| 83880 | <1% | 2,224 | $3K | |
| 81001 | <1% | 6,401 | $3K | |
| 73110 | <1% | 207 | $3K | |
| 93017 | <1% | 21 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,394 | $2K |
| 82947 | <1% | 2,414 | $2K | |
| 86140 | <1% | 621 | $2K | |
| 85610 | <1% | 3,573 | $2K | |
| J3490 | Unclassified drugs | <1% | 825 | $2K |
| 87040 | <1% | 2,331 | $2K | |
| A9270 | Non-covered item or service | <1% | 9,026 | $2K |
| 83735 | <1% | 3,347 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 16 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 63 | $2K |
| 81003 | <1% | 4,146 | $2K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 28 | $2K |
| 93976 | <1% | 12 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 673 | $2K |
| 94060 | <1% | 12 | $2K | |
| 87634 | <1% | 306 | $2K | |
| 80061 | Lipid panel | <1% | 101 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,344 | $1K |
| 86850 | <1% | 51 | $1K | |
| 83690 | <1% | 3,539 | $1K | |
| 73564 | <1% | 108 | $989.65 | |
| 90715 | <1% | 117 | $954.85 | |
| 82077 | <1% | 697 | $939.53 | |
| 86900 | <1% | 68 | $884.79 | |
| 80076 | <1% | 367 | $869.71 | |
| 80143 | <1% | 633 | $839.07 | |
| 87631 | <1% | 28 | $781.54 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,804 | $758.44 |
| 81025 | <1% | 2,097 | $643.69 | |
| 82607 | <1% | 32 | $624.99 | |
| 82550 | <1% | 674 | $618.66 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,389 | $605.08 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 871 | $588.81 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 160 | $576.77 |
| 82728 | <1% | 162 | $572.90 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 99 | $516.02 |
| 94729 | <1% | 13 | $487.41 | |
| 84702 | <1% | 580 | $479.96 | |
| 80179 | <1% | 621 | $450.33 | |
| 73502 | <1% | 28 | $413.64 | |
| 70486 | <1% | 16 | $399.64 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 37 | $380.18 |
| 85379 | <1% | 1,129 | $358.45 | |
| 82330 | <1% | 660 | $345.67 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 753 | $344.95 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 874 | $324.35 |
| 73080 | <1% | 15 | $324.29 | |
| 83540 | <1% | 140 | $308.13 | |
| 87075 | <1% | 912 | $296.85 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 946 | $292.58 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,408 | $266.33 |
| 85018 | <1% | 647 | $241.79 | |
| 85730 | <1% | 405 | $224.08 | |
| 83550 | <1% | 136 | $214.86 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 214 | $210.72 |
| 85652 | <1% | 243 | $207.53 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 126 | $205.25 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 564 | $202.56 |
| 84132 | <1% | 672 | $162.13 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,484 | $158.23 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 925 | $153.72 |
| 87077 | <1% | 315 | $146.76 | |
| 87449 | <1% | 198 | $145.22 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,012 | $142.27 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 361 | $140.81 |
| 82435 | <1% | 539 | $126.22 | |
| 87186 | <1% | 379 | $120.99 | |
| G0404 | Electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination | <1% | 19 | $113.43 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,016 | $103.02 |
| 86901 | <1% | 66 | $101.99 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 370 | $101.39 |
| 82248 | <1% | 98 | $92.60 | |
| 87205 | <1% | 30 | $85.93 | |
| 84295 | <1% | 541 | $82.72 | |
| 84100 | <1% | 117 | $75.85 | |
| 82150 | <1% | 143 | $46.91 | |
| 87081 | <1% | 100 | $45.67 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,225 | $42.06 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 404 | $37.70 |
| 94760 | <1% | 604 | $34.11 | |
| 36600 | <1% | 103 | $33.57 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 164 | $32.47 |
| J2704 | Injection, propofol, 10 mg | <1% | 877 | $28.57 |
| 76377 | <1% | 111 | $27.65 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,009 | $20.70 |
| 82962 | <1% | 35 | $19.38 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 529 | $18.38 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 39 | $15.28 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 268 | $14.90 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 631 | $14.44 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 785 | $14.04 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 136 | $11.67 |
| 82948 | <1% | 57 | $10.01 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 75 | $9.96 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 317 | $6.51 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 241 | $6.12 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 271 | $5.97 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 53 | $3.38 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 15 | $2.12 |
| 84145 | <1% | 20 | $0.75 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 22 | $0.57 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 28 | $0.00 |
| 99152 | 0% | 49 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 14 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 19 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 46 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 0% | 37 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 14 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 26 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 84 | $0.00 |
| 84703 | 0% | 29 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 58 | $0.00 |
| 80329 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHILLERO, ANTHONY (DIRECTOR, FP&A)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.